CHMP declares atypical femur stress fractures a bisphosphonate class effect
This article was originally published in Scrip
Experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) have concluded that rare atypical fractures of the femur are a class effect of bisphosphonates but that they should be retained to treat and prevent bone disorders. While the CHMP confirmed the benefits of bisphosphonates it recommends that a warning of the fracture risk be added to the prescribing information for all medicines containing bisphosphonates in the European Union.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.